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Abstract
Background: Radiotherapy for localised prostate cancer has many known and distressing side effects. The efficacy
of group interventions for reducing psychological morbidity is lacking. This study investigated the relative benefits
of a group nurse-led intervention on psychological morbidity, unmet needs, treatment-related concerns and
prostate cancer-specific quality of life in men receiving curative intent radiotherapy for prostate cancer.
Methods: This phase III, two-arm cluster randomised controlled trial included 331 men (consent rate: 72 %; attrition:
5 %) randomised to the intervention (n = 166) or usual care (n = 165). The intervention comprised four group and
one individual consultation all delivered by specialist uro-oncology nurses. Primary outcomes were anxious and
depressive symptoms as assessed by the Hospital Anxiety and Depression Scale. Unmet needs were assessed with
the Supportive Care Needs Survey-SF34 Revised, treatment-related concerns with the Cancer Treatment Scale and
quality of life with the Expanded Prostate Cancer Index −26. Assessments occurred before, at the end of and 6
months post-radiotherapy. Primary outcome analysis was by intention-to-treat and performed by fitting a linear
mixed model to each outcome separately using all observed data.
Results: Mixed models analysis indicated that group consultations had a significant beneficial effect on one of two
primary endpoints, depressive symptoms (p = 0.009), and one of twelve secondary endpoints, procedural concerns
related to cancer treatment (p = 0.049). Group consultations did not have a significant beneficial effect on
generalised anxiety, unmet needs and prostate cancer-specific quality of life.
Conclusions: Compared with individual consultations offered as part of usual care, the intervention provides a
means of delivering patient education and is associated with modest reductions in depressive symptoms and
procedural concerns. Future work should seek to confirm the clinical feasibility and cost-effectiveness of group
interventions.
Trial registration: Australian and New Zealand Clinical Trials Registry ANZCTRN012606000184572. 1 March 2006.
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Background
Radiotherapy is a commonly prescribed curative treatment
for localised prostate cancer. Radiotherapy, however, has
many known and distressing side effects including bowel
and urinary urgency or incontinence and erectile dysfunc-
tion; these may persist many years post-treatment [1].
Enduring side effects can result in unmet needs [2], poorer
health-related quality of life (HRQOL) [3] and ongoing
psychological maladjustment [4–6]. Notably, such dif-
ficulties are pronounced in those receiving androgen
deprivation therapy [1, 7].
The need for evidence-based interventions is clear,
especially given the prevalence of prostate cancer and
the often favourable long-term prognosis associated with
localised disease [8]. Extant supportive care trials suggest
that group-based interventions, involving one health pro-
fessional and a group of patients, may provide an efficient
and effective mode of delivering disease, treatment and
self-management information [9]. More intensive, group-
based interventions may also provide HRQOL and benefit
finding advantages over basic information provision
[10–12]. Specific evidence of efficacy for ameliorating psy-
chological morbidity is lacking, but, to date, the impact of
group-based interventions tailored to the expressed needs
of group participants has not been evaluated. Further,
previous trials have not targeted men commencing treat-
ment at the same time.
The phase III randomised controlled trial (RCT) re-
ported in this article assessed the relative benefits of a tai-
lored, group consultation intervention for men receiving
curative intent radiotherapy for prostate cancer compared
with current best practice supportive care (or usual care)
alone. Group consultations aimed to communicate infor-
mation about diagnosis, treatment and side effects along
with coaching in self-management. Group consultation
content and discussions were tailored based on expressed
needs and concerns. The primary hypothesis was that the
group consultations would have a significant beneficial
effect on psychological morbidity (anxious and depressive
symptoms) compared with usual care alone. It was also
hypothesised that the group consultations would have a
significant beneficial effect on treatment-related concerns,
unmet needs and prostate cancer-specific HRQOL.
Methods
Design
A two-arm, cluster RCT was used, intervention arm
(n = 165) and control arm (n = 166); key components and
timing are shown in Fig. 1. The unit of randomisation was
all consenting patients scheduled to commence curative
intent external beam radiotherapy for prostate cancer at
two treatment sites within defined, consecutive fortnights.
This ensured clusters allocated to the intervention arm
would contain sufficient numbers of men to form a group
and groups comprised men at similar stages in their
treatment trajectory. Clusters were randomised remotely
to the intervention or current best practice by a weighted-
biased coin method. Neither participants nor statisticians
were blinded. Participants were not blinded, because
this is impossible in supportive care trials. Statisticians
were unblinded after all trial outcome data was
collected, but before preparation of the CONSORT flow
diagram and outcome analyses. Randomisation was
stratified by treatment site. Assessments occurred pre-
treatment (T1), at the end of treatment (T2) and 6 months
post-treatment (T3).
Setting
This study was conducted at two sites of a specialist
oncology facility, Peter MacCallum Cancer Centre, in
Australia.
Sample
Eligibility criteria required a confirmed diagnosis of
prostate cancer; 18 years or older; commencing radical
external beam radiotherapy with curative intent (with or
without brachytherapy); and able to understand English.
Patients with a serious cognitive or psychological
disorder; who were scheduled to received palliative
radiotherapy; having brachytherapy alone, had previous
radiotherapy treatment; or deemed too unwell by the
treatment team were excluded.
Usual care: best practice supportive care
A nurse-led clinic forms part of usual care. All prostate
cancer patients attend a minimum of one individual
consultation with a specialist uro-oncology or radiation
oncology nurse, then as required throughout their treat-
ment. Nurses provide written information about treat-
ment and side effects; referrals may be initiated also.
Intervention: group consultations
Development and content of the group consultation
intervention has been described in detail previously [13],
so only a brief description follows.
The intervention package was designed to: 1) system-
atically assess patient needs and values to direct the
content of consultations; 2) provide timely information
on basic prostate anatomy, side effects, treatment and
survivorship issues at critical points in the treatment
trajectory; 3) coach men in evidence-based self-care and
communication strategies with their treatment team to
assist them to achieve optimal health status; and 4) offer
a forum for psychosocial peer support and information
exchange. It consists of four group consultations and
one individual consultation.
All consultations comprising the intervention package
were delivered by a specialist uro-oncology nurse. Group
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consultations were scheduled at critical times in the
illness/treatment trajectory when patients often experi-
ence increased information needs and distress – specific-
ally, beginning of treatment (week 1), mid-treatment
(week 4), treatment completion (week 7) and 6-weeks
post-treatment (week 13). The individual consultation
was scheduled after the beginning of treatment group
consultation. Note, also, that men could attend additional
individual consultations after the mid-treatment and
treatment completion group consultations as required.
The beginning of treatment group consultation focused
on preparing men for radiotherapy treatment. The mid-
treatment group consultation focused on educating men
about common treatment side-effects and relevant self-
care strategies and normalising the impact of these side
effects. The treatment completion consultation rein-
forced and elaborated on the content and discussions of
the mid-treatment session to maximise the use of self-
care and communication strategies. The treatment com-
pletion consultation also focused on helping men achieve
a sense of closure following treatment and manage any
concerns the may have had for the future (e.g., returning
to work). The 6-weeks post-treatment consultation dealt
with possible late sexual side effects of radiotherapy
treatment and cancer survivorship issues including fear
of cancer recurrence.
Parts of the beginning of treatment consultation and
most of the mid-treatment consultation were tailored to
the needs of group participants based on their responses
to two separate question prompt lists. Men’s responses
to the question prompt list administered at the begin-
ning of treatment group consultation were also used to
guide their individual consultation with the intervention
nurse.
Fig. 1 Participant flow following CONSORT guidelines
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Application of intervention protocol
Group-based consultations of approximately one hour
were run by one of three specialist uro-oncology nurses
trained in group facilitation skills and the intervention
package. An intervention manual, summarising details of
the intervention, was developed to support nurse train-
ing. Specialist uro-oncology nurses had minimal inter-
action with men allocated to usual care to reduce
‘contamination’ between arms. If intervention patients
were unable to attend in person, they joined the group
consultation via telephone or received a catch-up
session.
Quality assurance
36 of 193 tape-recorded consultation sessions were
randomly selected and assessed for adherence to the
intervention protocol by an independent rater against a
checklist of intervention elements. On average, 74 % of
the intervention manual content was delivered, consist-
ent with the tailored nature of the material.
Recruitment and assessment procedures
A trained research assistant identified and approached
potentially eligible participants from outpatient clinic
and treatment lists between 2nd January 2007 and 18th
December 2009. Written informed consent and baseline
self-report questionnaires were completed prior to ran-
domisation. Follow-up questionnaires were completed at
hospital appointments or at home and returned via post.
Measures
Demographic and clinical information for consenters
and decliners was gathered from medical records. Reasons
for refusal were recorded.
Psychological morbidity and global distress were
assessed with the Hospital Anxiety and Depression Scale
(HADS). The 14-item HADS comprises two subscales
designed to assess anxious (HADS-A) and depressive
(HADS-D) symptomatology in the past week [14]. The
single-item DT provides a measure of global distress
experienced in the past 7 days [15]. Cancer treatment-
related concerns were measured with the Cancer Treat-
ment Scale (CaTS) [16]. The 25-item CaTS comprises
two subscales assessing patients’ sensory/psychological
and procedural concerns about their upcoming treat-
ment. Unmet supportive care needs were assessed with
the Supportive Care Needs Survey short-form revised
(SCNS-SF34-R). The 34-item SCNS-SF34-R comprises
five subscales measuring levels of unmet psychological,
health system and information, physical and daily living,
patient care and support and sexuality needs in the
last month [17]. Prostate cancer-specific HRQOL was
assessed with the Expanded Prostate Cancer Index
Composite short-form (EPIC-26) [18]. The 26-item
EPIC-26 comprises four subscales examining function-
ing and symptom bother relevant to the urinary,
bowel, hormonal and sexual domains.
Power considerations
Using methods proposed by Eldridge et al. [19], the esti-
mated design effect for the study was 1.17 (based on 100
clusters of average size 4, a coefficient of variation for
cluster size of 0.25 and a conservative at-worst intra-
class correlation of 0.05) [20]. Initial sample size calcula-
tions incorporated this estimated design effect and were
calculated for feasible treatment effect differences of
0.35 SD for continuous outcomes. To achieve at least
80 % power at a 5 % significance level, 130 × 1.17 = 152
patients in each arm were required.
Statistical analysis
Pearson’s χ2 or Fisher’s exact test for nominal variables,
Mann–Whitney U-tests for ordinal variables and inde-
pendent samples t-tests for continuous variables were
used to compare characteristics of study participants
and study decliners. Descriptive statistics were used to
examine questionnaire compliance and summarise patient
characteristics and responses to outcomes measures by
study arm at baseline and follow-up assessments.
Primary outcome analysis was by intention-to-treat and
performed by fitting a linear mixed model to each out-
come separately using all observed data. Missing data im-
putation was not undertaken. Three-level models (Level 1,
time point; Level 2, participant; and Level 3, cluster) in-
cluding random intercepts and slopes were constructed
for each outcome following recommended procedures for
multi-level modelling [21]. Fully parameterised models
also included fixed effects for time (linear and quadratic
components: time and quadtime), group (usual care, inter-
vention), site (1, 2), pre-baseline androgen deprivation
therapy (pre-BL ADT: yes, no) plus two-way and cross-
level interactions. Pre-BL ADT was included as a covariate
as previous research indicates a robust relationship be-
tween hormone therapy and study outcomes [1, 7], but
parameters were retained only if normal distribution
tests were significant and the more elaborate models
provide a better fit to the data. Random slope terms
were also only retained if there was significant variance
between participants.
As a secondary descriptive analysis, individual change
scores were calculated between T1 and follow-ups at T2
and T3. The within-group effect size was calculated as
the mean change from baseline divided by the standard
deviation at baseline. The between-group effect size was
calculated as the difference between study arms in mean
change from baseline divided by the pooled standard
deviation of change [22].
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All exploratory and descriptive analyses were performed
with SPSS Windows Version 18.0 (SPSS, Chicago, IL,
USA). Outcome analyses were performed with MLwiN
Version 2.1 [23].
Results
Trial profile
Of 589 patients who were eligible for the study (Fig. 1),
468 patients were approached and 337 consented to
participate (72 % consent rate). Of the 331 patients
randomised, 166 were allocated to usual care via 48
clusters (median size 2 patients, IQR 2–4) and 165 to
the intervention via 52 clusters (median size 3 patients,
IQR 2–4.75).
Apart from a higher consent rate at one site (p = 0.02),
none of the associations between patient characteristics
and response status or group differences between
consenters and decliners were statistically significant
(Table 1). Study arms appeared well balanced in terms of
baseline characteristics (Table 1).
Intervention fidelity
All four group consultation sessions were delivered to 47
intervention clusters; 1–3 sessions were delivered to the
remaining 5 clusters. In total, 113 participants attended all
group consultations, 34 attended three, 10 attended two, 3
one, and 5 none. The reasons for missed consultations
were: scheduling issues, distance from hospital, study
withdrawal, patient too unwell or no reason given. Of the
52 men who missed at least one session, 18 attended a
catch-up consultation.
Questionnaire compliance
Questionnaire compliance was high: > 96 of participants
provided data on all outcomes at T1, > 95 at T2 and >
92 % at T3 (available on request from the authors).
Outcome analyses
Descriptives for outcome measures by study arm at
baseline and follow-up assessments are provided in
Table 2. Results from the mixed models and secondary
descriptive analyses are provided in Tables 3 and 4 re-
spectively (estimates of variance components and cluster
level ICC are available on request from the authors).
Primary outcomes
Depressive symptoms
For HADS-D, apart from the site by time interactions,
all fixed effects were statistically significant (all p > 0.05;
Table 3). The difference in the rate of change on the
HADS-D for the intervention group relative to the usual
care group was significant (p = 0.0009). Change in the
rate of change was also significant (p = 0.001).
Irrespective of group, patients who had received pre-BL
ADT had higher levels of depressive symptoms at
baseline (p < 0.0001) and exhibited greater reductions in
these symptoms at T2 and T3 compared with those who
had not received ADT (p = 0.008).
Descriptive analysis indicated a slight reduction in
depressive symptoms in the intervention group between
baseline and end of RT, whereas the usual care group re-
ported an increase in these symptoms in the same time
period (M chg = −0.2 and 0.6 respectively; M diff = −0.8,
95 % CI: −1.2, −0.3, Table 4). The effect size for the
between-groups difference at the end of radiotherapy
was 0.37. The difference between groups persisted 6
months post-RT, although the between-groups difference
in mean changes was substantially reduced (M diff = −0.3,
95 % CI: −0.9, 0.2; effect size = 0.14).
Anxious symptoms
For HADS-A, the difference in rate of change for the
intervention group relative to the usual care group was
not significant (p = 0.42, Table 3). Irrespective of group,
pre-BL ADT patients exhibited a lower rate of decline in
anxiety per follow-up compared with those who had not
received pre-BL ADT (p = 0.008).
Descriptive analysis indicated a reduction in anxious
symptoms for both groups at follow-up assessments
from baseline levels (Table 2). However, consistent
with the mixed models results, differences in mean
changes from baseline at the end of radiotherapy (M
diff = −0.2, 95 % CI: −0.8, 0.4; effect size = 0.09) and 6
months post-radiotherapy (M diff = 0.0, 95 % CI: −0.7,
0.7; effect size = 0.01) were negligible.
Secondary outcomes
Global distress
For the DT, the difference in rate of change for the inter-
vention group relative to the usual care group was not
significant (p = 0.16, Table 3). Irrespective of group, pre-
BL ADT patients reported higher levels of global distress
at baseline (p = 0.008). The effect sizes for between-
groups differences in mean changes at both follow-ups
were 0.15 and 0.1 respectively (Table 4).
Prostate cancer-specific HRQoL
For EPIC-26 domains, none of the differences in rate of
change for the intervention group relative to the usual
care group were significant (all p > 0.05, Table 3).
Notably, however, for the Bowel and Urinary summaries,
model coefficients for time and quadtime were highly
significant (all p < 0.001) and pre-BL ADT patients
exhibited a significantly greater decline in urinary scores
per follow-up compared with those who had not received
pre-BL ADT (p < 0.0025).
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Table 1 Patient demographic and clinical characteristics of consenters (by study arm) and decliners
Consenters P
Usual care Intervention Decliners
(N = 166) (N = 165) (N = 115)
n % n % n %
Oncology facility 0.02
Site 1 70 42.2 70 42.4 64 55.7
Site 2 96 57.8 95 57.6 51 44.3
Age at baseline, years 0.30
Mean 67.6 67.2 68.1
Standard Deviation 6.7 6.9 7.9
Range 46–85 51–84 44–82
<65 54 32.5 56 33.9 32 27.8
≥65 112 67.5 109 66.1 83 72.2
Marital status
Married/defacto 136 81.9 127 77.0
Other 30 18.1 38 23.0
Location 0.14
Urban 136 81.9 136 82.4 101 87.8
Rural 30 18.1 29 17.6 13 11.3
Missing 1
Risk group (D’Amico, 1998) 0.16
Low 11 10.6 11 11.6 4 3.9
Intermediate 44 42.3 39 41.1 37 35.9
High 49 47.1 45 47.4 38 36.9
Scheduled treatment 0.29
Salvage EBRT 61 36.7 69 41.8 31 27.0
Brachytherapy followed by EBRT 8 4.8 9 5.5 8 7.0
EBRT followed by brachytherapy 5 3.0 3 1.8 1 0.9
EBRT alone 92 55.4 84 50.9 70 60.9
Previous treatment
Any previous treatment 0.60
No 39 23.5 34 20.6 28 24.3
Yes 127 76.5 131 79.4 87 75.7
Active surveillance 1.00
No 148 89.2 153 92.7 105 91.3
Yes 18 10.8 12 7.3 10 8.7
Prostatectomy 0.15
No 105 63.3 96 58.2 79 68.7
Yes 61 36.7 69 41.8 36 31.3
Androgen deprivation 0.49
No 113 68.1 116 70.3 75 65.2
Yes 53 31.9 49 29.7 40 34.8
P-value relates to comparison of consenters versus decliners. Other marital status includes never married, separated/divorced and widowed. Risk groups were
designated for men who did not undergo surgery
EBRT external beam radiotherapy, TURP transurethral resection of the prostate
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Table 2 Descriptives for study measures by study arm at baseline and follow-up assessments
Assessment
Baseline/before radiotherapy End of radiotherapy 6 months post-radiotherapy
Outcome by study arm M SD M SD M SD
Hospital Anxiety and Depression Scale
Anxiety
Usual care 4.5 (3.5) 3.8 (3.2) 3.9 (3.3)
Intervention 4.4 (3.5) 3.4 (3.1) 3.8 (3.8)
Depression
Usual care 2.6 (2.8) 3.1 (2.9) 3.0 (3.2)
Intervention 2.8 (2.9) 2.6 (2.4) 2.9 (2.9)
Distress Thermometer
Usual care 2.0 (2.2) 2.1 (2.3) 1.7 (2.1)
Intervention 1.9 (2.3) 1.7 (2.3) 1.5 (2.3)
Expanded Prostate cancer Index Composite
Bowel
Usual care 92.9 (12.4) 77.6 (20.1) 86.5 (16.8)
Intervention 93.5 (12.7) 80.6 (18.2) 87.6 (14.7)
Urinary
Usual care 84.5 (16.1) 73.6 (17.9) 83.5 (16.8)
Intervention 85.2 (14.9) 76.0 (17.5) 83.0 (16.0)
Sexual
Usual care 31.8 (28.7) 26.2 (25.4) 27.2 (26.7)
Intervention 27.0 (25.8) 23.8 (23.1) 25.0 (24.6)
Hormonal
Usual care 84.3 (18.3) 82.5 (17.3) 83.4 (18.6)
Intervention 82.9 (19.1) 83.1 (18.5) 84.4 (19.8)
Supportive Care Needs Survey
Psychological
Usual care 23.9 (21.4) 19.6 (21.2) 15.6 (21.0)
Intervention 22.7 (21.4) 18.4 (20.4) 14.7 (20.0)
Health system & information
Usual care 28.4 (30.2) 21.4 (24.2) 17.0 (23.7)
Intervention 27.1 (29.4) 19.3 (25.6) 13.2 (21.1)
Patient care & support
Usual care 12.1 (18.2) 12.2 (18.6) 8.3 (16.0)
Intervention 11.1 (17.9) 9.9 (16.1) 9.0 (19.2)
Physical & daily living
Usual care 13.7 (22.1) 19.6 (21.2) 15.6 (21.0)
Intervention 11.5 (18.1) 18.4 (20.4) 14.7 (20.0)
Sexual
Usual care 26.5 (29.4) 22.9 (28.3) 27.2 (30.8)
Intervention 27.2 (29.6) 22.4 (27.7) 26.1 (28.3)
Cancer Treatment Survey
Procedural
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For both usual care and intervention groups, descriptive
analysis indicated medium- to large-sized deterioration
in urinary (effect size for within-group changes = 0.68
and 0.62, respectively) and bowel functioning (effect
size for within-group changes = 1.34 and 0.99, respect-
ively) at the end of RT compared to baseline levels
(Table 4). Six months post-RT, however, urinary func-
tioning was comparable with baseline levels for both
groups (effect size for within-group changes = 0.06 and
0.15, respectively), whereas bowel functioning was still
somewhat worse (effect size for within-group changes =
0.55 and 0.57 respectively). Effect sizes for all between-
groups differences in mean changes at both follow-ups
were trivial- to small-sized (range = 0.04 to 0.16; Table 4).
Unmet supportive care needs
For SCNS-SF34-R domains, none of the differences in
rate of change for intervention relative to usual care
were significant (all p > 0.05, Table 3). Notably, baseline
levels of patient care and support and physical and daily
living needs were very low (i.e., estimates for Intercept,
Table 3). Effect sizes for all between-groups differences
in mean changes at both follow-ups were trivial- to
small-sized (range = 0.02 to 0.15; Table 4).
Cancer treatment-related concerns
There was a significant reduction in both types of cancer
treatment-related concerns for both groups between base-
line and end of RT (both p < 0.001; Table 3). Relative to
the usual care group, there was a statistically significant
reduction in procedural concerns for the intervention
group (p = 0.049), however no intervention benefit was
observed for sensory/psychological concerns (p = 0.46).
The effect size for the between-groups difference for
procedural concerns was 0.24 (Table 4).
Discussion
This study assessed the relative benefits of a tailored,
group consultation intervention for men receiving cura-
tive intent radiotherapy for prostate cancer compared
with current best practice supportive care alone. A key
innovation was the requirement that group content and
discussions be tailored based on men’s expressed needs
and concerns. Information provided was high-quality,
evidence-based and appropriately timed. Discussions
provided opportunities for peer support, including
emotional and practical sharing, and men often saw each
other in the treatment clinic waiting rooms, reinfor-
cing their shared experience. Intervention fidelity was
moderate: all four group consultations were delivered to
47 of 52 (90 %) clusters and a majority of intervention
participants attended all four group consultations (113 of
165) or a catch-up consultation (18 of 52).
A modest intervention benefit was demonstrated on
one of two primary outcomes, depressive symptoms, and
one of twelve secondary outcomes, treatment-related
procedural concerns. The intervention benefit for de-
pressive symptoms was most evident at the end of radio-
therapy; compared to baseline, intervention participants
reported a slight reduction in depressive symptoms,
whereas usual care participants reported an increase in
these symptoms. The benefit for treatment-related pro-
cedural concerns was also observed at the end of radio-
therapy. Intervention benefits as assessed by all other
study outcomes were trivial- to small-sized and non-
significant.
This is the first trial of a group-based intervention for
prostate cancer patients to demonstrate a significant
beneficial effect on depressive symptoms, as assessed by
the HADS-D. Previous trials using depression as an out-
come have shown little, if any, impact on depressive
symptoms in the short- or long-term [24, 25]. Notably,
items comprising the HADS-D concentrate on an inabil-
ity to experience pleasure [26]. Evidence suggests anhe-
donia is more common than depressed mood among
prostate cancer patients, possibly because of reduced
sources of pleasure or reduced ability to access those
sources [27]. Speculatively, participation in our group
consultation intervention may have helped to normalise
men’s experiences and bolster hope, offsetting the
increase in depressive symptoms reported by usual care
participants. Previously tested interventions either
provided no or substantially fewer opportunities for peer
support, which has been emphasised as a possible mech-
anism of effect in group-based interventions [9, 11, 25].
While the size of the benefit on depressive symptoms
Table 2 Descriptives for study measures by study arm at baseline and follow-up assessments (Continued)
Usual care 2.7 (1.0) 1.9 (.9)
Intervention 2.7 (1.1) 1.8 (.9)
Sensory/psychological
Usual care 2.3 (.9) 1.7 (.7)
Intervention 2.3 (.9) 1.6 (.8)
For the Hospital Anxiety and Depression Scale, higher scores reflect higher levels of anxious and depressive symptomatology. For the Distress Thermometer,
higher scores reflect higher levels of distress. For the Expanded Prostate cancer Index Composite-26, higher scores reflect higher quality of life/better functioning/
lower bother. For the Supportive Care Needs Survey (Short Form with Revised response scale), higher scores reflect higher levels of unmet need. For the Cancer
Treatment Scale, higher scores reflect higher levels of cancer treatment-related concerns
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was modest (effect size = 0.37), it should be considered
in the context of floor effects on the HADS-D and the
medium-to-large-sized deterioration in prostate cancer-
specific HRQOL following radiotherapy.
The intervention benefit on treatment-related proced-
ural concerns is also noteworthy. Together with the results
from our recent trial of a nurse-led pre-chemotherapy
education intervention [28], the current findings sug-
gest that well-structured and appropriately timed
nurse-led consultations can be effective in reducing
cancer treatment-related concerns, especially those
related to the procedural aspects of treatment.
Table 3 Mixed models results for primary and secondary outcomes: estimates of fixed effects
Parameter HADS DT EPIC-26
Anxiety Depression Bowel Urinary Sexual Hormonal
est s.e. est s.e. est s.e. est s.e. est s.e. est s.e. est s.e.
Intercept 3.9 * 0.4 1.5 ** 0.3 1.5 ** 0.3 94.5 ** 1.9 85.0 ** 2.0 38.6 ** 3.1 92.2 ** 1.9
Time −1.3 ** 0.4 0.8 ** 0.3 −0.2 0.3 −24.7 ** 2.5 −14.2 ** 2.1 −4.4 2.3 0.1 1.8
Quadtime 0.3 ** 0.1 −0.2 * 0.1 0.0 0.1 5.9 ** 0.6 3.6 ** 0.5 0.8 0.5 −0.1 0.4
Group 0.6 0.5 1.0 * 0.5 0.3 0.3 1.0 2.6 0.2 2.6 −5.7 4.2 −5 2.6
Site 1.1 * 0.6 1.1 * 0.5 0.7 0.3 −2.2 2.3 −1.1 2.4 −2.4 3.9 −2.2 2.4
Pre-BL ADT 1.3 * 0.5 2.2 ** 0.5 0.8 ** 0.3 −0.9 2.4 0.3 2.0 −16.6 ** 2.9 −20.4 ** 1.6
Group × Site −1.4 * 0.7 −1.4 * 0.6 −0.8 0.4 1.7 2.8 1.0 3.2 1.3 5.2 4.8 3.2
Group × Pre-BL ADT −5.2 3.0
Site × Pre-BL ADT −2.3 ** 0.7 −1.6 ** 0.6 −1.0 0.4
Group × Time −0.3 0.4 −1.0 ** 0.3 −0.5 0.3 3.6 2.5 2.2 2.1 2.7 2.4 2.3 1.9
Group × Quadtime 0.1 0.1 0.2 ** 0.1 0.1 0.1 −0.9 0.6 −0.7 0.5 −0.5 0.6 −0.4 0.5
Time × Site 0.5 0.4 0.4 0.3 0.6 0.3 5.6 * 2.5 3.5 2.1 −4.2 2.4 −4.2 * 2.0
Quadtime × Site −0.1 0.1 −0.1 0.1 −0.1 0.1 −1.5 * 0.6 −0.9 0.5 0.9 0.6 1.0 * 0.5
Time × Pre-BL ADT 0.2 ** 0.1 −0.9 ** 0.3 4.2 2.7 −6.9 ** 2.3 1.2 * 0.6
Quadtime × Pre-BL ADT 0.2 * 0.1 −1.2 0.6 1.5 ** 0.5
Parameter SCNS-SF34-R CaTS
Psychological Health system
& information
Patient care
& support
Physical &
daily living
Sexuality Procedural Sensory/
psychological
Intercept 18.8 ** 2.5 26.4 ** 3.0 8.7 ** 2.0 6.4 ** 2.4 20.3 ** 3.3 2.6 ** 0.1 2.1 ** 0.1
Time −7.2 ** 2.3 −9.0 ** 3.5 0.3 2.4 8.2 ** 2.5 −5.2 3.4 −0.8 ** 0.1 −0.6 ** 0.1
Quadtime 1.2 * 0.5 1.4 0.8 −0.4 0.6 −1.9 ** 0.6 1.1 0.8
Group 4.2 3.2 0.3 3.9 1.3 2.7 1.7 3.1 5.4 4.4 0.0 0.2 0.1 0.1
Site 7.1 * 3.2 −0.3 3.7 3.4 2.5 7.5 * 2.9 6.7 4.1 0.0 0.1 0.2 0.1
Pre-BL ADT 9.0 ** 3.0 6.7 ** 2.5 4.4 ** 1.7 9.3 ** 2.0 7.4 * 2.9 0.2 * 0.1 0.2 ** 0.1
Group × Site −10.0 ** 3.8 −2.4 4.7 −3.9 3.2 −6.3 3.8 −7.8 5.4 0.0 0.2 −0.1 0.2
Site × Pre-BL ADT −9.0 * 4.0
Group × Time −3.2 2.5 −0.9 3.8 −1.7 2.7 1.0 2.7 −1.5 3.7 −0.2 * 0.1 −0.1 0.1
Group × Quadtime 0.7 0.6 0.1 0.9 0.6 0.6 −0.1 0.6 0.3 0.9
Time × Site 3.9 2.5 1.3 3.9 0.4 2.7 −0.6 2.7 0.4 3.7 0.2 0.1 0.1 0.1
Quadtime × Site −0.7 0.6 0.0 0.9 0.1 0.6 0.1 0.6 0.2 0.9
The coefficient for each group by time interaction represents the average difference in rate of change for the intervention group relative to the usual care group.
The coefficient for each group by quadtime interaction represents the average difference in “change” in the rate of change (acceleration or deceleration) for the
intervention group relative to the usual care group
Time represents average number of months since first assessment. Reference categories: group, usual care; site, Site 2; and pre-BL ADT, no. Time modelled as a
random effect for HADS Anxiety and Depression, EPIC-26 Hormonal and Sexual Summary and SCNS-SF34-R Psychological and Sexuality. Terms for the interaction
between Pre-BL ADT and Group, Time and Quadtime were not included in the final models for SCNS-SF34-R and CaTS subscales. In all other cases where the
estimate of a coefficient is not provided, the relevant term was not included in the final model. * p < .05; ** p < .01
Variance components are available from the authors
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There was no evidence that group consultations
afforded a prostate cancer-specific HRQOL advantage or
provided benefits in terms of unmet needs. Previous tri-
als have used general HRQOL as an outcome [10–12],
rather than prostate cancer-specific HRQOL, making it
impossible to compare the results. Nevertheless, recent
evidence suggests that functioning and symptom bother
related to prostate cancer and its treatment may require
much more targeted and intensive intervention than that
offered to either study arm in this trial [29].
Regarding limitations, the current trial was conducted
in a specialist cancer centre with a high standard of
usual care. Men randomised to usual care also received
evidence-based information about upcoming treatment,
Table 4 Mean change from baseline and effect size at the end of radiotherapy and 6 months post-radiotherapy
Usual care Intervention Between-groups
difference
95 % CI Effect
sizeMean change
from baseline
95 % CI Effect size Mean change
from baseline
95 % CI Effect
size
End of radiotherapy
HADS Anxiety −0.7 −1.2, −0.3 0.21 −1.0 −1.4, −0.6 0.29 −0.2 −0.8, 0.4 0.09
Depression 0.6 0.3, 0.9 0.21 −0.2 −0.6, 0.1 0.07 −0.8 −1.2, −0.3 0.37
DT 0.1 −0.3, 0.5 0.05 −0.3 −0.7, 0.2 0.12 −0.4 −0.9, 0.2 0.15
EPIC-26 Urinary −11.0 −13.4, −8.6 0.68 −9.2 −11.5, −6.9 0.62 1.8 −1.5, 5.1 0.12
Bowel −15.7 −18.4, −12.9 1.34 −12.8 −15.8, −9.8 0.99 2.9 −1.1, 6.9 0.16
Sexual −5.2 −7.9, −2.5 0.18 −2.8 −5.5, −0.2 0.11 2.4 −1.4, 6.1 0.14
Hormonal −1.8 −4.0, 0.3 0.10 0.0 −2.2, 2.2 0.00 1.9 −1.2, 4.9 0.14
SCNS-SF34-R Physical & daily
living
6.0 3.0, 9.1 0.27 6.8 4.0, 9.7 0.37 0.8 −3.3, 5.0 0.04
Psychological −4.1 −6.9, −1.3 0.20 −6.7 −9.4, −4.0 0.32 −2.6 −6.5, 1.3 0.15
Sexuality −3.8 −7.8, 0.2 0.13 −4.9 −9.3, −0.5 0.17 −1.1 −7.0, 4.8 0.04
Patient care and
support
0.2 −2.5, 2.9 0.01 −0.8 −3.9, 2.3 0.05 −1.0 −5.1, 3.1 0.05
Health system
& information
−6.9 −11.0, −2.9 0.23 −7.6 −12.4, −2.8 0.26 −0.7 −6.9, 5.6 0.02
CaTS Sensory/
psychological
−0.6 −0.7, −0.5 0.64 −0.7 −0.8, −0.5 0.72 −0.1 −0.3, 0.1 0.10
Procedural −0.7 −0.9, −0.6 0.71 −1.0 −1.1, −0.8 0.86 −0.2 −0.5, −0.02 0.24
6 months post-radiotherapy
HADS Anxiety −0.6 −1.1, −0.2 0.18 −0.6 −1.1, −0.1 0.18 0.0 −0.7, 0.7 0.01
Depression 0.4 0.04, 0.8 0.16 0.1 −0.3, 0.5 0.04 −0.3 −0.9, 0.2 0.14
DT −0.3 −0.6, 0.04 0.14 −0.5 −0.8, −0.2 0.21 −0.2 −0.7, 0.3 0.10
EPIC-26 Urinary −1.0 −2.9, 0.9 0.06 −2.2 −4.5, 0.1 0.15 −1.2 −4.2, 1.8 0.09
Bowel −6.8 −9.4, −4.3 0.55 −6.2 −8.5, −3.9 0.57 0.6 −2.8, 4.1 0.04
Sexual −4.4 −8.0, −0.9 0.15 −2.1 −5.1, 0.9 0.08 2.3 −2.4, 7.1 0.11
Hormonal −0.8 −3.2, 1.6 0.05 1.3 −1.3, 4.0 0.07 2.2 −1.4, 5.7 0.14
SCNS-SF34-R Physical &
daily living
1.7 −1.4, 4.8 0.07 3.4 0.7, 6.1 0.19 1.8 −2.3, 5.9 0.10
Psychological −7.2 −10.2, −4.3 0.35 −8.0 −10.8, −5.3 0.39 −0.8 −4.9, 3.3 0.04
Sexuality 0.0 −4.6, 4.5 0.00 −1.2 −5.5, 3.1 0.04 −1.2 −7.4, 5.1 0.04
Patient care
and support
−3.5 −6.1, −1.0 0.20 −1.7 −4.9, 1.5 0.10 1.8 −2.3, 5.9 0.10
Health system
& information
−10.9 −14.9, −7.0 0.37 −13.4 −17.8, −9.0 0.46 −2.5 −8.4, 3.5 0.09
Effect sizes for changes from baseline = (Mean change from baseline/standard deviation at baseline)
Effect sizes for between-groups differences = ((Intervention Mean change from baseline) – (Usual Care Mean change from baseline)) / pooled standard deviation
for change. For HADS, DT, SCNS-SF34-R and CaTS, a score decrease reflects improvement; as such, between-groups differences with a negative sign indicate a
greater improvement (or lesser deterioration) among intervention participants. For EPIC-26, a score increase reflects improvement; as such, between-groups
differences with a positive sign indicate a greater improvement (or lesser deterioration) among intervention participants
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likely side effects and self-care strategies; however the
precise details of information provided in usual care
were not assessed. Intervention effects, or the lack
thereof, should be considered in this context. Further,
with the exception of sexual functioning, baseline func-
tioning was uniformly high. While not so at the time this
trial was designed, it is now widely recognised that floor
effects (and/or not preselecting trial participants based
on the need for help) may inadvertently lead to an
underestimation of intervention effects [30].
Traditionally, psycho-educational interventions have
been formulaic and didactic with static content. They
have comprised people with different cancers, people at
different stages in the illness trajectory and people
receiving different treatments. The current trial design
ensured group consultations were composed of men at a
very similar stage in the treatment trajectory: all
commencing potentially curative treatment for prostate
cancer, then receiving daily radiotherapy across approxi-
mately the same timeframe. Tailoring ensured the rele-
vance of educational content and group discussions to
all participants and had a significant beneficial effect on
depressive symptoms and procedural concerns.
Conclusions
HRQOL and unmet needs advantages were not observed,
but, arguably, these findings suggest that group consulta-
tions provide an efficient and effective means of delivering
patient education. Future work should seek to confirm the
clinical feasibility of implementing this nurse-led group
consultation, particularly amongst men who have depres-
sive symptoms.
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